Quarter Comparison
Revenue
Operating Income
Gross Margin
Net Margin
Income Statement
Cash Flow Statement
Balance Sheet
Earnings Release
EX-99.1 2 ex_1004692.htm EXHIBIT 99.1 ex_1004692.htm Exhibit 99.1 ImmuCell ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026 For Immediate Release PORTLAND, Maine – August 13, 2026 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health
EX-99.1 2 ex_1004692.htm EXHIBIT 99.1 ex_1004692.htm Exhibit 99.1 ImmuCell ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026 For Immediate Release PORTLAND, Maine – August 13, 2026 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced its unaudited financial results for the quarter ended June 30, 2026. Management ’ s Discussion: “Today we are reporting net income of $1.8 million for the second quarter of 2026,” commented Timothy C. Fiori, Chief Financial Officer of ImmuCell. “Revenue grew 11.5% to $7.2 million in the second quarter of 2026, which is a strong positive market signal in the face of high revenue in the second quarter of 2025 driven by distributor-restocking after a prolonged period of back...
Source
Exhibit EX-99.1
0001437749-26-027667
Filed August 13, 2026 at 8:07 PM UTC. The figures above are from the audited statements, not from this release.